StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) shareholders

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
97M of 85M shares
Institutional holders
275
48 new, 26 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
2 buys · 274 sales
Net sold $300.79M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (14.30%)
11,681,45014.30%13G (passive) amendmentMar 31, 2026
T. Rowe Price Associates, Inc.8,873,58810.70%13G (passive) amendmentAug 31, 2026
Julian C. Baker
Joint filing with Baker Bros. Advisors LP (10.90%), Baker Bros. Advisors (GP) LLC (10.90%) and 1 more
8,676,79710.90%13D (active) amendmentDec 9, 2025
Behzad Aghazadeh
Joint filing with Avoro Capital Advisors LLC (9.99%)
7,750,0009.99%13G (passive) amendmentSep 30, 2024
Wellington Management Company LLP
Joint filing with Wellington Management Group LLP (9.20%), Wellington Group Holdings LLP (9.20%) and 1 more
5,996,8739.00%13G (passive) amendmentMar 31, 2025
FMR LLC
Joint filing with Abigail P. Johnson (8.20%)
5,879,6118.20%13G (passive) amendmentSep 30, 2025
T. Rowe Price Investment Management, Inc.5,460,2576.70%13G (passive)Mar 31, 2026
BlackRock, Inc.5,450,2866.60%13G (passive) amendmentSep 30, 2026
Wellington Group Holdings LLP
Joint filing with Wellington Management Group LLP (7.70%), Wellington Investment Advisors Holdings LLP (7.70%) and 1 more
5,372,0617.70%13G (passive) amendmentJun 30, 2025
Lampert Mark N
Joint filing with Bvf Partners L P/Il (6.30%), Bvf Inc/Il (6.30%) and 1 more
5,237,1516.30%13D (active) amendmentJun 26, 2026
Wellington Investment Advisors Holdings LLP
Joint filing with Wellington Management Group LLP (5.50%), Wellington Group Holdings LLP (5.50%) and 1 more
4,412,9335.50%13G (passive) amendmentDec 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of KYMRValueChange% of portfolio
FMR LLC12,349,25614.47%$1.42B+649,3060.06%
Baker Bros. Advisors LP8,657,24210.14%$992.73M–4.97%
Avoro Capital Advisors LLC7,474,7478.76%$857.13M–7.70%
Price T Rowe Associates Inc /Md/7,112,9808.33%$815.65M+1,052,1330.08%
T. Rowe Price Investment Management, Inc.6,257,2617.33%$717.52M+792,2640.47%
BlackRock, Inc.5,538,2106.49%$635.07M+477,3340.01%
Bvf Inc/Il3,872,0524.54%$444.01M−1,630,65811.35%
Wellington Management Group Llp3,675,0284.30%$421.42M−214,6590.07%
Vanguard Portfolio Management LLC2,992,1933.50%$343.11M+118,1370.02%
Siren, L.L.C.2,935,8303.44%$336.65M−251,0006.81%
Vanguard Capital Management LLC2,932,3783.43%$336.26M+52,0540.01%
Atlas Venture Life Science Advisors, LLC2,847,5413.34%$326.53M−1,730,46737.05%
State Street Corp2,737,2263.21%$313.88M+347,4590.01%
Geode Capital Management, LLC1,816,3312.13%$208.32M+170,9810.01%
Capital Research Global Investors1,388,8811.63%$159.26M−284,3940.02%
Goldman Sachs Group Inc1,187,3331.39%$136.15M+298,9240.01%
UBS Group AG1,007,7771.18%$115.56M−16,0750.01%
Alliancebernstein L.P.981,5211.15%$81.75M+93,4860.03%
Driehaus Capital Management LLC919,2331.08%$105.41M−124,3500.61%
Merck & Co., Inc.772,1650.90%$88.54M–16.82%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202627597M100.0%48 / 9783 / 268M7M
Q1 202625696M100.0%43 / 9673 / 3816M4M
Q4 202525590M100.0%68 / 9963 / 1514M5M
Q3 202521081M94.9%40 / 8154 / 388M6M
Q2 202521079M92.5%64 / 6952 / 2610M4M
Q1 202517373M85.4%23 / 6457 / 296M4M
Q4 202418072M84.0%33 / 6060 / 287M4M
Q3 202417669M81.0%37 / 5465 / 1613M7M
Q2 202415768M79.1%25 / 5850 / 304M5M
Q1 202416469M80.6%42 / 5944 / 1313M5M
Q4 202313661M71.9%33 / 3752 / 187M3M
Q3 202312157M67.2%12 / 4936 / 202M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

357 funds held KYMR in Q2 2026, 28% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of KYMRValue% of fundAs of
T. Rowe Price New Horizons Fund, Inc.2,257,2072.64%$258.83M1.76%Jun 30, 2026
Fidelity Growth Company Fund2,185,4072.56%$177.94M0.18%May 31, 2026
Vanguard Total Stock Market Index Fund2,089,2492.45%$239.57M0.01%Jun 30, 2026
T. Rowe Price Capital Appreciation Fund2,046,1042.40%$234.63M0.33%Jun 30, 2026
Vanguard Health Care Fund1,796,4692.10%$185.75M0.49%Jul 31, 2026
iShares Russell 2000 ETF1,607,6491.88%$184.35M0.22%Jun 30, 2026
Vanguard Small-Cap Index Fund1,509,7571.77%$173.12M0.09%Jun 30, 2026
SMALLCAP World Fund Inc1,352,2481.58%$155.06M0.16%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,272,7541.49%$145.95M1.36%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.924,9671.08%$106.07M0.89%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund868,9151.02%$99.64M0.21%Jun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.790,0930.93%$90.60M0.97%Jun 30, 2026
Vanguard Extended Market Index Fund726,5450.85%$83.31M0.09%Jun 30, 2026
Vanguard Explorer Fund693,2270.81%$71.68M0.32%Jul 31, 2026
Fidelity Small Cap Index Fund684,7500.80%$70.80M0.21%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Nello MainolfiChief Executive Officer, Director666,5680.78%Oct 1, 2026
Brian AdamsChief Legal Officer50,2540.06%Sep 4, 2026
Terence RooneyChief Medical Officer38,0000.04%Jul 27, 2026
Noah GoodmanChief Business Officer47,1790.06%Jul 2, 2026
Bruce N. JacobsChief Financial Officer248,0830.29%Jul 2, 2026
Jeremy G. ChadwickChief Operating Officer44,6180.05%May 27, 2026
Jared GollobChief Medical Officer117,1340.14%Mar 4, 2026
Ellen ChiniaraChief Legal Officer82,3260.10%Mar 3, 2025
Bruce BoothDirector2,396,4262.81%Jul 2, 2026
Ii Gp Llc BvfDirector2,104,0752.46%Jun 26, 2026
Value Fund L. P. BiotechnologyDirector2,104,0752.46%Jun 26, 2026
Gp Holdings Llc BvfDirector––Jun 26, 2026
Inc/Il BvfDirector2,195,6962.57%Jun 26, 2026
I. Gp Llc BvfDirector294,6320.35%Jun 26, 2026
Value Fund Ii Lp BiotechnologyDirector1,671,0481.96%Jun 26, 2026
Mark N. LampertDirector2,494,6882.92%Jun 26, 2026
Value Trading Fund OS LP BiotechnologyDirector2,350,5032.75%Jun 26, 2026
Partners L. P/Il BvfDirector1,627,9281.91%Jun 26, 2026
Partners OS Ltd. BVFDirector––Jun 26, 2026
Jeffrey W. AlbersDirector5,0000.01%Jun 25, 2026
Victor SandorDirector––Jun 25, 2026
John MaraganoreDirector––Jun 25, 2026
667, L.P.Director, 10% owner5,516,9866.46%Jun 25, 2026
Elena RidloffDirector0–Jun 25, 2026
Bros. Advisors (GP) LLC BakerDirector, 10% owner6,117,2957.17%Jun 25, 2026
Brothers Life Sciences LP BakerDirector, 10% owner––Jun 25, 2026
Felix BakerDirector, 10% owner7,955,9169.32%Jun 25, 2026
Pamela EspositoDirector1,0000.00%Jun 25, 2026
Julian BakerDirector, 10% owner––Jun 25, 2026
Gorjan HrustanovicDirector––Jun 25, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−262$116.12$30.42K666,568
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−8,230$115.40$949.74K666,830
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−7,601$114.43$869.78K675,060
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−4,876$113.24$552.16K682,661
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−5,506$112.42$618.98K687,537
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−3,525$111.44$392.83K693,043
Nello Mainolfi
Chief Executive Officer, Director
Oct 1, 2026Option exercise+30,000$2.08$62.40K696,568
Brian Adams
Chief Legal Officer
Sep 4, 2026Sale−2,137$117.57$251.25K50,254
Brian Adams
Chief Legal Officer
Sep 4, 2026Sale−3,025$116.81$353.35K52,391
Brian Adams
Chief Legal Officer
Sep 4, 2026Sale−1,209$115.55$139.70K55,416
Terence Rooney
Chief Medical Officer
Jul 27, 2026Award+38,000––38,000
Nello Mainolfi
Chief Executive Officer, Director
Jul 7, 2026Sale(10b5-1 plan)−50,000$119.00$5.95M666,568
Nello Mainolfi
Chief Executive Officer, Director
Jul 7, 2026Option exercise+50,000$2.08$104.00K716,568
Nello Mainolfi
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−3,336$116.56$388.84K666,568
Nello Mainolfi
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−24,105$114.96$2.77M713,954
Nello Mainolfi
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−44,050$115.69$5.10M669,904
Nello Mainolfi
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−6,626$113.98$755.23K738,059
Nello Mainolfi
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−1,883$112.80$212.40K744,685
Nello Mainolfi
Chief Executive Officer, Director
Jul 1, 2026Option exercise+80,000$2.08$166.40K746,568
Noah Goodman
Chief Business Officer
Jul 1, 2026Sale(10b5-1 plan)−3,389$114.29$387.33K47,179
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−6,153$116.99$719.84K248,083
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−3,200$117.70$376.64K244,883
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−7,971$115.82$923.20K254,236
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Option exercise+61,378$5.33$327.14K321,992
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−1,500$110.54$165.81K320,492
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−1,700$111.57$189.67K318,792
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−51,375$114.77$5.90M262,207
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−4,110$114.19$469.32K313,582
Bruce N. Jacobs
Chief Financial Officer
Jun 30, 2026Sale(10b5-1 plan)−1,100$112.79$124.07K317,692
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−934$111.20$103.86K2,384,685
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−5,549$105.78$586.97K2,446,375
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−14,798$106.63$1.58M2,431,577
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−19,419$107.76$2.09M2,412,158
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−130$111.20$14.46K462,856
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−1,078$110.67$119.30K462,986
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−1,104$109.75$121.16K464,064
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−1,498$108.28$162.20K465,168
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−2,698$107.76$290.74K466,666
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−2,133$106.63$227.44K469,364
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−770$105.78$81.45K471,497
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−7,723$110.67$854.70K2,385,619
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−7,968$109.75$874.49K2,393,342
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−10,848$108.28$1.17M2,401,310
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−3,024$107.76$325.87K466,077
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−2,318$106.63$247.17K469,101
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−848$105.78$89.70K471,419
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−19,093$107.76$2.06M2,412,747
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−14,613$106.63$1.56M2,431,840
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−5,471$105.78$578.72K2,446,453
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−1,239$109.75$135.98K463,150
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−1,688$108.28$182.78K464,389
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−907$111.20$100.86K2,385,747
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−7,602$110.67$841.31K2,386,654
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−1,199$110.67$132.69K461,951
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−157$111.20$17.46K461,794
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−7,833$109.75$859.67K2,394,256
Bruce Booth
Director
Jun 29, 2026Sale(10b5-1 plan)−10,658$108.28$1.15M2,402,089
Bruce Booth
Director
Jun 26, 2026Sale(10b5-1 plan)−1,729$118.66$205.16K472,267
Bruce Booth
Director
Jun 26, 2026Sale(10b5-1 plan)−3,069$117.85$361.68K473,996
Bruce Booth
Director
Jun 26, 2026Sale(10b5-1 plan)−1,701$117.09$199.17K477,065

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
15.96%
8M shares short
Days to cover
10.5
At 1M shares a day
Change since last report
-8.4%
From 9M shares
Short volume, 20 days
58.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kymera Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,096 shares on Sep 11, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Nello Mainolfi
Officer, Director
Oct 1, 202630,000$3.35MOct 1, 2026Exercise of stock options
Brian Adams
Officer
Sep 4, 20266,371$747.19KSep 4, 2026Shares acquired upon vesting of Restricted Stock Units awarded under the Issuer's 2020 Equity Incentive Plan.
Jeremy G. Chadwick
Officer
Sep 2, 202610,879$1.30MSep 2, 2026Exercise of Stock Options
Nello Mainolfi
Officer, Director
Jul 7, 202650,000$5.95MJul 7, 2026Exercise of stock options
Nello Mainolfi
Officer, Director
Jul 2, 202680,000$9.14MJul 1, 2026Exercise of stock options
Noah Goodman
Officer
Jul 1, 20263,389$388.62KJul 1, 2026Restricted Stock Units
Bruce N. Jacobs
Officer
Jun 30, 202677,109$8.43MJun 30, 2026Exercise of Stock Options
Atlas Venture Opportunity Fund I, L.P.
Shareholder
Jun 29, 202610,473$1.13MJun 29, 2026Private Placement
Atlas Venture Fund X, L.P.
Shareholder
Jun 29, 202666,177$7.16MJun 29, 2026Private Placement
Atlas Venture Opportunity Fund I, L.P.
Shareholder
Jun 26, 202657,451$6.69MJun 26, 2026Private Placement
Atlas Venture Fund X, L.P.
Shareholder
Jun 26, 2026410,427$47.80MJun 26, 2026Private Placement
Partners L. P/Il Bvf
Affiliate of Director
Jun 26, 20261,630,658$189.91MJun 26, 2026Acquired upon the automatic conversion of private shares in connection with the Issuer's initial public offering on August 21, 2020. The private shares were acquired and fully paid for on March 11, 20
Atlas Venture Opportunity Fund I, L.P.
Shareholder
Jun 25, 202667,329$6.72MJun 25, 2026Private Placement
Atlas Venture Fund X, L.P.
Shareholder
Jun 25, 2026480,992$48.04MJun 25, 2026Private Placement
Noah Goodman
Officer
Jun 25, 20265,000$499.35KJun 25, 2026Exercise of Stock Options

See a number that looks wrong?